Navigation Links
NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September. The first presentation will take place on September 11th, 2009 at 11:40am as part of the Rodman & Renshaw 11th Annual Healthcare Conference in New York, New York. The second presentation will take place on September 23, 2009 at 4:15pm as part of the Life Sciences Summit 2009 in Hauppauge, New York. All times are local time.

Dr. Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

About NexGenix: NexGenix Pharmaceuticals Holdings, Inc. is a privately-held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 300 potential compounds. From this group, three lead drug candidates have been identified on the basis of superior efficacy, safety, and the ability to cross the blood brain barrier. The product profiles lend themselves to address diseases such as glioblastoma (or "glioma", commonly known as malignant brain tumor) and other cancers, as well as neurodegenerative disorders including the motor neuron disease ALS (Lou Gehrig's disease) and Parkinson's disease. Each of these indications represents a world-wide market of at least $1B/year. In addition, the Company has a clinical stage intralesional treatment for dermal neurofibromas, the most co
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
4. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
5. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
6. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
7. Rib-X Pharmaceuticals to Present at the 49th ICAAC
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
10. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... China Sky One,Medical, Inc. ("China Sky One Medical" ... fully integrated pharmaceutical company developing and producing,over-the-counter drugs ... that the Company has 30 medicines that will ... Basic Medical Insurance, Industrial Injury Insurance,and Maternity Insurance ... 30 medicines treat a variety of common ailments ...
(Date:12/15/2009)... Va., Dec. 15 AstraZeneca (NYSE: ... of Virginia (UVa) in Charlottesville, today announced ... research collaboration to enhance development of new ... with a secondary focus on peripheral vascular ... ) ,, The collaborative preclinical research projects ...
(Date:12/15/2009)... N.Y., Dec. 15 The International Society ... the professional society is continuing to accept abstracts ... held in Arlington, VA, April 19-21, 2010. This ... encouraging non-members to join the organization to submit ... submission deadline is 12 AM EST, January 15, ...
(Date:12/15/2009)... and LONDON, Dec. 15 ... Thomson Pharma ® has become the first drug ... protocol and outcome information. This highly anticipated new ... customers this month. ,, Thomson ... intelligence from registries, publications, press releases, conferences, and ...
Breaking Biology Technology:China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2
... Eppendorf Perfectprep Gel Cleanup Kit , , ... Cleanup Kit , , , , , ... 5 Prime, Inc. , October 1, 2002, , , ... Agarose gel electrophoresis is a method used to separate and analyze , ...
... , , , , ... Comments , Microinjection is the loading or transfer of ... tip of the glass microcapillary , has an inner diameter ... back loaded with the substance to be transferred into the cells , ...
... , , , , , ... quantitative analysis of nucleic acids , and proteins has ... It includes absorption measurements in the ultraviolet and in the visibility , ... at 260 , nm and colorimetric protein determination is ...
Other Biology Technology:Eppendorf Perfectprep Gel Cleanup Kit 2Eppendorf Perfectprep Gel Cleanup Kit 3Eppendorf Perfectprep Gel Cleanup Kit 4Eppendorf Perfectprep Gel Cleanup Kit 5Eppendorf Perfectprep Gel Cleanup Kit 6Sample Preparation for Microinjection 2Sample Preparation for Microinjection 3Sample Preparation for Microinjection 4Sample Preparation for Microinjection 5Sample Preparation for Microinjection 6Sample Preparation for Microinjection 7Quantification made easy 2Quantification made easy 3
(Date:12/16/2009)... 8, 2009 National Instruments (Nasdaq: ... measurement and control, and DENSO Robotics, a ... robotics technology, today announced their collaboration to ... DENSO robotic arms. The collaboration increases productivity ... flexible manufacturing applications. In today,s trend toward ...
(Date:12/15/2009)... COLUMBIA, Mo. As soon as babies are ... as jaundice and e-coli. For up to a month, ... Although these infections are often minor, they can lead ... newborns, immune systems, University of Missouri researchers have pinpointed ... lead to an immune-strengthening vaccine. , "We,re trying to ...
(Date:12/15/2009)... VIB and Ghent University in Flanders, Belgium have found ... the major cause of death in intensive care units. ... in mice with septic shock, researchers Anje Cauwels and ... less damage, while their chances of survival increased significantly. ... assumed that nitric oxide is responsible for the potentially ...
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Researchers work on vaccine to improve immune system in newborns 2Septic shock: Nitric oxide beneficial after all 2Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference 56822 1Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference 56822 2NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 56819 1NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 56819 2NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 56819 3NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 56819 4Regions Hospital Selected to Participate in National Cardiac Care Quality Improvement Effort 56815 1Regions Hospital Selected to Participate in National Cardiac Care Quality Improvement Effort 56815 2Regions Hospital Selected to Participate in National Cardiac Care Quality Improvement Effort 56815 3
... an observational study by researchers at the University of ... and 80 years of age who received treatment for ... men who did not receive treatment. The study will ... Journal of the American Medical Association. , Thanks to ...
... cases, scientists at Johns Hopkins have discovered the genetic origins ... the leading reason for corneal transplantation in the United States. ... the cells covering the clear, outermost lens of the eye ... Late in life, the dystrophy causes swelling of the cornea ...
... efficient propulsion of squid, jellyfish and other cephalopods, a ... new generation of compact vortex generators that could make ... vehicles at low speeds and with greater precision. , ... plots of two classic sci-fi films - may soon ...
Other Biology News:Older men treated for early prostate cancer live longer than those who are not 2Leading reason for corneal transplants comes into focus 2Leading reason for corneal transplants comes into focus 3Squid-inspired design could mean better handling of underwater vehicles 2
... for the synthesis of 5' capped RNA ... of cap analog for a large portion ... transcription reaction results in the incorporation of ... of the transcripts. Capped mRNAs are generally ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... is available as a one-cabinet ...
... iEMS Incubator/Shaker HT is designed ... iEMS Incubator/Shaker HT is ideal ... hybridization and primer extension assays. ... as a one-cabinet model, allowing ...
... Pseudomonas atlantica Description: Beta-Agarase is useful ... from low-melting-temperature agarose. Beta-Agarase digests the ... User Friendly Properties: Heat Inactivation: 65C, ... Optimum pH: 6.5 Purity: Tested for ...
Biology Products: